Digital health technologies are transforming clinical research by providing new ways to measure patient health, function, and treatment response. Wearable sensors, connected devices, smartphones, and remote monitoring platforms now generate continuous streams of data.
Such data can reveal insights previously unavailable through traditional clinical assessments. As sponsors explore these technologies, two terms frequently emerge in conversations around study design and regulatory strategy: digital biomarkers and digital endpoints.
While these concepts are closely related, they are not interchangeable. In fact, misunderstanding the distinction can create confusion during endpoint development, validation planning, regulatory discussions, and evidence generation activities.
For sponsors designing modern clinical trials, understanding the relationship between digital biomarkers and digital endpoints is essential. The distinction influences how measurements are developed, validated, interpreted, and used to support clinical and regulatory decision making.
This article explains the difference between digital biomarkers and digital endpoints and explores why the distinction matters. It also outlines how sponsors can successfully incorporate both into clinical development programs.
Understanding the Digital Biomarkers vs Digital Endpoints Debate
Digital biomarkers and digital endpoints are related concepts, but they serve different functions in clinical research.
A digital biomarker is an objective, quantifiable physiological or behavioral measurement collected through a digital device. The device can be a wearable sensor, smartphone, or connected health technology.
A digital endpoint is a trial outcome measure that uses one or more digital biomarkers to assess treatment effects, disease progression, or other study objectives.
In simple terms, digital biomarkers are the measurements, while digital endpoints are the outcomes derived from those measurements. For example, a wearable sensor may continuously collect movement data from patients with Parkinson’s disease.
The movement measurements themselves may function as digital biomarkers. When those measurements are analyzed and incorporated into a predefined clinical outcome used to evaluate treatment effectiveness, they become part of a digital endpoint.
Understanding this distinction is important because the scientific, operational, and regulatory requirements for biomarkers and endpoints are not always the same.
Understanding Digital Biomarkers
Digital biomarkers are the foundational building blocks of digital measurement. They represent objective observations collected through digital technologies and are designed to capture specific aspects of physiology, behavior, or health status.
Unlike traditional biomarkers that may rely on laboratory testing, imaging, or biological samples, digital biomarkers are often generated through continuous or high-frequency monitoring in real-world environments. Examples of digital biomarkers include:
- Walking speed measured through wearable sensors
- Daily physical activity levels
- Sleep duration and sleep efficiency
- Heart rate variability
- Respiratory rate patterns
- Tremor characteristics
- Gait stability measurements
These measurements provide objective information about patient health and functioning. The value of digital biomarkers lies in their ability to capture aspects of daily life that may not be observable during clinic visits.
By generating continuous data, sponsors can gain a more complete understanding of disease progression, symptom variability, and treatment response.
However, a digital biomarker alone does not necessarily serve as a clinical trial outcome measure. Additional development is typically required before a measurement can support a study endpoint.
Understanding Digital Endpoints
Digital endpoints are clinical trial outcomes that incorporate data collected through digital technologies.
Just as traditional clinical endpoints help determine whether a treatment is effective, digital endpoints use digitally derived measurements to evaluate outcomes relevant to a study’s objectives.
A digital endpoint may be based on a single digital biomarker or a combination of multiple digital biomarkers. For example:
- Changes in mobility over time may serve as a digital endpoint in a neurological trial.
- Sleep quality improvements may function as a digital endpoint in a sleep disorder study.
- Physical activity recovery following treatment may serve as a digital endpoint in a cardiovascular study.
Digital endpoints are designed to answer specific clinical questions.
While a digital biomarker captures data, a digital endpoint provides a framework for interpreting that data within the context of a clinical trial. This distinction becomes particularly important when sponsors engage with regulators, statisticians, clinicians, and healthcare decision makers.
Digital Biomarkers vs Digital Endpoints: A Practical Comparison
Although the two concepts are closely connected, several important differences distinguish digital biomarkers from digital endpoints. Here is a comparison overview of both.
| Digital Biomarkers | Digital Endpoints |
| Objective measurements collected through digital technologies | Clinical trial outcomes derived from digital measurements |
| Focus on physiological or behavioral data | Focus on evaluating treatment effects or study objectives |
| May exist independently of a clinical trial endpoint | Defined within a clinical trial framework |
| Provide raw or processed measurements | Provide interpretable clinical outcomes |
| Often serve as inputs to endpoint development | Used to assess efficacy, safety, or clinical benefit |
An easy way to understand the relationship is to think of digital biomarkers as ingredients and digital endpoints as the finished product. The biomarker provides the measurement.
The endpoint provides the context, interpretation, and clinical relevance necessary for decision-making. Both are important, but they fulfill different roles within clinical research.
Why Sponsors Frequently Confuse these Terms?
The terms digital biomarker and digital endpoint are often used interchangeably throughout industry discussions, conference presentations, and technology marketing materials. This confusion occurs because the concepts are closely linked.
Many digital endpoints rely directly on digital biomarkers. As a result, discussions about one often include references to the other.
Additionally, the rapid evolution of digital health technologies has introduced new terminology into clinical research. Definitions continue to mature as sponsors, regulators, technology providers, and research organizations gain experience with digital measurement.
Sponsors may also encounter situations where a digital biomarker eventually becomes part of a digital endpoint development strategy. This progression can blur distinctions between measurement generation and endpoint application.
Despite these overlaps, maintaining clear terminology is important because validation requirements, evidence generation strategies, and regulatory expectations may differ depending on whether the focus is on a biomarker or an endpoint.
Why the Difference Matters for Clinical Trials?
Understanding the distinction between digital biomarkers and digital endpoints has practical implications throughout the clinical development process. It is important because:
Study Design Decisions
Sponsors must determine early whether a digital measure will serve as an exploratory measurement, a biomarker, a secondary endpoint, or a primary endpoint. Each use case may require different levels of evidence and validation. Clear definitions help ensure that study objectives, statistical plans, and data collection strategies remain aligned.
Validation Strategy
Validation requirements vary depending on how a measurement will be used. A digital biomarker intended for exploratory research may require a different validation approach than a digital endpoint intended to support regulatory submissions. Understanding the intended role of a measure helps sponsors develop appropriate evidence generation plans.
Regulatory Engagement
Regulatory agencies focus heavily on the context of use. Sponsors must clearly communicate whether a digital measure functions as a biomarker, an endpoint, or both. Precise terminology supports more productive regulatory discussions and reduces ambiguity during review processes.
Clinical Relevance
Digital biomarkers may provide valuable information about physiology or behavior. However, digital endpoints must go further by demonstrating relevance to clinical outcomes, treatment effects, or patient experience.
This additional layer of interpretation often determines whether a measure can support decision-making within a trial. By distinguishing between biomarkers and endpoints, sponsors can establish clearer development pathways and stronger evidence strategies.
How Digital Biomarkers Become Digital Endpoints?
One of the most important concepts for sponsors to understand is that digital biomarkers often serve as the foundation for digital endpoint development. The process typically follows several stages. Let us take a look at the different stages of the process.
Identify a Meaningful Clinical Concept
The process begins by defining the health outcome that is most relevant to patients, clinicians, and regulators. Sponsors must first determine what aspect of disease, functioning, or treatment response they want to measure.
For instance, mobility in a neurological disorder, sleep quality in a respiratory condition, physical function in a musculoskeletal disease, or disease progression in a chronic illness. Establishing a clearly defined concept of interest ensures that all subsequent measurement activities align with the study’s clinical objectives.
Select Appropriate Technologies
Next, sponsors must identify digital technologies capable of capturing meaningful data related to that outcome. This often involves evaluating wearable sensors, smartphone applications, connected medical devices, or other digital health technologies.
Technology selection should be driven by scientific evidence rather than device popularity or technical features alone. The chosen technology must accurately measure the intended concept while also meeting the practical requirements of study participants, sites, and research teams.
Develop Digital Biomarkers
After a suitable technology has been selected, the collected sensor data must be processed to produce meaningful measurements. Raw data streams rarely provide immediate clinical value without additional analysis and interpretation.
These processed measurements become digital biomarkers that reflect specific aspects of patient health or behavior. For example, raw accelerometer signals may be transformed into measures of walking speed, physical activity levels, or gait characteristics that provide insight into patient functioning.
Establish Validation Evidence
Before a digital biomarker can support clinical decision making, sponsors must demonstrate that it is reliable, accurate, and clinically meaningful. This requires a structured validation strategy that evaluates both the measurement itself and its relationship to patient outcomes.
Validation activities may include analytical testing, reliability assessments, clinical studies, and comparisons with established measures. The goal is to generate evidence that shows the digital biomarker consistently captures the concept it is intended to measure.
Build Digital Endpoints
Once a digital biomarker has been sufficiently validated, it can be incorporated into predefined clinical trial outcomes. At this stage, the measurement moves beyond data collection and becomes part of a framework to evaluate treatment effectiveness, disease progression, or other study objectives.
These resulting outcomes are digital endpoints. Since they are directly tied to trial objectives and clinical decision-making, digital endpoints often play a central role in efficacy assessments, regulatory submissions, and evidence-generation strategies.
This progression demonstrates why digital biomarkers and digital endpoints should be viewed as complementary rather than competing concepts. Digital biomarkers provide the measurements, while digital endpoints provide the clinical context and interpretation to translate those measurements into meaningful trial outcomes.
Regulatory Considerations for Digital Biomarkers and Digital Endpoints
As interest in digital measurement grows, regulatory agencies continue to emphasize scientific rigor and evidence generation. The FDA is evaluating whether a measurement is fit for purpose. For both digital biomarkers and digital endpoints, sponsors must demonstrate several aspects.
They must have a clear scientific rationale that is defined by measurement reliability. Moreover, the process must demonstrate analytical and clinical validity relevant to the intended context of use. This ensures that the trial has meaningfulness to patients and clinicians.
Digital endpoints often face additional scrutiny because they are used directly to evaluate study outcomes. As a result, sponsors should consider regulatory strategy early in the development process rather than waiting until study execution is underway.
Organizations with expertise in digital measurement science can help sponsors navigate these requirements and build evidence packages to support future submissions.
The Future of Digital Measurement in Clinical Research
Digital biomarkers and digital endpoints will continue to play an increasingly important role in clinical development.
Advances in wearable sensors, artificial intelligence, machine learning, and remote monitoring technologies are creating new opportunities to understand patient health outside traditional clinical settings.
Future clinical trials are likely to incorporate more continuous, objective, and patient-centered measurements. As this evolution continues, sponsors will need robust frameworks for distinguishing between measurements and outcomes.
It will ensure that digital biomarkers are developed appropriately and translated into clinically meaningful digital endpoints. The organizations that succeed will be those that combine technological innovation with rigorous validation and regulatory planning.
Advancing Digital Measurement With VivoSense
Successfully developing digital biomarkers and digital endpoints requires expertise that spans wearable sensor technology, clinical science, biostatistics, validation, and regulatory strategy.
VivoSense helps sponsors transform sensor-generated data into scientifically meaningful measurements and clinically relevant outcomes.
Through expertise in digital biomarkers, digital endpoint development, wearable sensor validation, and evidence generation, VivoSense supports sponsors seeking to build robust digital measurement strategies for modern clinical trials.
Explore VivoSense resources on digital biomarkers and digital endpoints to learn how specialized digital measurement expertise can strengthen your next clinical development program.
Frequently Asked Questions
Can a digital biomarker become a digital endpoint?
Yes. A digital biomarker may serve as the foundation for a digital endpoint when it is incorporated into a predefined clinical outcome used to evaluate treatment effects or disease progression.
Are digital biomarkers regulated differently from digital endpoints?
Both require validation and evidence generation, but digital endpoints often face additional scrutiny because they directly support clinical trial objectives and regulatory decision-making.
Can a digital endpoint include multiple digital biomarkers?
Yes. Many digital endpoints combine multiple digital biomarkers to create a more comprehensive measure of patient health, function, or treatment response.
Why are digital biomarkers important for patient-centered drug development?
Digital biomarkers can capture real-world aspects of patient experience, including mobility, sleep, activity, and daily functioning, providing insights that may not be observable during clinic visits.
What is the first step in developing a digital endpoint?
The first step is identifying a clinically meaningful concept of interest that matters to patients, clinicians, and regulators. This concept then guides biomarker selection, validation, and endpoint development.